Our streamlined drug screening workflow begins with the selection of your PDO model of interest within your target therapeutic area. Depending on your desired biological endpoint (i.e. cell viability, immune cell activation, epithelial barrier function, etc) we will design a scope of work and carry out the experiment. At study completion, we will provide a tailored report.
Patient-derived organoid screening platform
PDO Screen is built upon the recent success of our organoid screening platform which led to the first oncology agent to be approved for clinical trials within 5 years of development. Select from a pre-set panel of patient-derived organoid models among the available tissue types for a fast, cost-efficient, and patient-relevant evaluation of your agent efficacy.
NEWS AND INSIGHTS